Eris Lifesciences Balance Sheet
- Market cap
- ₹15,937 crore
- P/E
- 24.8
- P/B
- 4.08
- ROE
- 18.3%
- Dividend yield
- 1.20%
As of Mar 2022, Eris Lifesciences had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 36.88% from Mar 2023.
Eris Lifesciences balance sheet
As at each financial year end, newest first. H1 = half-year.
| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 500 | 13.6 | 13.6 | 13.62 | 13.85 |
| Reserves | 8,500 | 2,156 | 2,541 | 2,793 | 3,407 |
| Borrowings | 1,200 | 877 | 2,781 | 2,478 | 2,359 |
| Other liabilities | 3,500 | 570 | 1,037 | 1,287 | 1,111 |
| Total liabilities | 13,700 | 3,667 | 7,040 | 7,036 | 7,366 |
| Fixed assets | 6,500 | 389 | 569 | 756 | 981 |
| Capital work in progress | 400 | 100 | 100 | 100 | 100 |
| Investments | 2,500 | 733 | 1,408 | 1,407 | 1,473 |
| Other assets | 4,300 | 1,100 | 2,112 | 2,111 | 2,210 |
| Total assets | 13,700 | 3,667 | 7,040 | 7,036 | 7,366 |
Balance sheet ratios
- Debt to equity
- 0.13
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Eris Lifesciences balance sheet — frequently asked questions
What is the total debt of Eris Lifesciences?
Eris Lifesciences reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹877 crore as of Mar 2023.
What is Eris Lifesciences' debt-to-equity ratio?
Based on the Mar 2022 balance sheet, Eris Lifesciences' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.
What are Eris Lifesciences' total assets?
Eris Lifesciences' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.
Same Data For Peers
Trade Eris Lifesciences With ATS
Track ERIS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.